IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 1201-1225 out of 1310.

<< < 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 > >>

Public Release: 13-Nov-2015
AACR Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved
New model helps predict breast cancer risk in Hispanic women
The first breast cancer risk-prediction model based entirely on data from Hispanic women, including whether a woman was born in or outside of the United States, provided a more accurate assessment of Hispanic women's risk of developing breast cancer compared with existing models based on data from non-Hispanic women, according to a study presented at the AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, held Nov. 13-16.
NIH/National Cancer Institute

Contact: Lauren Riley
lauren.riley@aacr.org
215-446-7155
American Association for Cancer Research

Public Release: 13-Nov-2015
AACR Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved
Healthy diet may reduce risk of ovarian cancer in African-American women
A healthy diet may reduce the risk of ovarian cancer in African-American women, according to data presented at the Eighth American Association for Cancer Research Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, held Nov. 13-16.
NIH/National Cancer Institute

Contact: Lauren Riley
lauren.riley@aacr.org
215-446-7155
American Association for Cancer Research

Public Release: 12-Nov-2015
Spine
'No evidence' that bone-growth agent for spinal fusion increases cancer risk
A new study may alleviate concerns regarding increased cancer risk for patients undergoing spinal fusion surgery with recombinant human bone morphogenetic protein. The study appears in Nov. 15 issue of Spine, published by Wolters Kluwer.

Contact: Connie Hughes
Connie.Hughes@wolterskluwer.com
646-674-6348
Wolters Kluwer Health

Public Release: 12-Nov-2015
Cancer Cell
Blood sample new way of detecting cancer
A new RNA test of blood platelets can be used to detect, classify and pinpoint the location of cancer by analysing a sample equivalent to one drop of blood. Using this new method for blood-based RNA tests of blood platelets, researchers have been able to identify cancer with 96 per cent accuracy. This according to a study at Umeå University in Sweden recently published in the journal Cancer Cell.

Contact: Daniel Harju
daniel.harju@umu.se
46-725-522-918
Umea University

Public Release: 12-Nov-2015
New England Journal of Medicine
Lenalidomide plus rituximab produces durable responses in mantle cell lymphoma patients
New research from Moffitt Cancer Center and its collaborators find that the drug combination rituximab plus lenalidomide was effective and produced long-term responses in patients with mantle cell lymphoma. The results from the multicenter phase 2 study were published in the Nov. 5 issue of The New England Journal of Medicine.

Contact: Steven Blanchard
steve.blanchard@moffitt.org
813-475-1718
H. Lee Moffitt Cancer Center & Research Institute

Public Release: 12-Nov-2015
Thyroid
Thyroid cancer biomarker assays may show inaccurate readings
Two thyroid cancer biomarkers go through a clumping cycle that may interfere with cancer detection tests. New research from Michigan Technological University explores a driving force behind the problem: a protein with a sweet tooth.
Michigan Tech, Research Excellence Fund

Contact: Tarun Dam
tkdam@mtu.edu
906-487-2940
Michigan Technological University

Public Release: 12-Nov-2015
JAMA Oncology
Personalized anti-nausea therapy better for cancer patients, Ottawa researchers
World-first trial published in JAMA-Oncology shows younger patients, women, those with history of either pregnancy-associated morning sickness or travel sickness, lower alcohol consumption, at greater risk of nausea and vomiting
Canadian Breast Cancer Research Foundation - Ontario Chapter, The Ottawa Hospital Foundation

Contact: Mark Shainblum
mshainblum@toh.ca
613-737-8460
Ottawa Hospital Research Institute

Public Release: 12-Nov-2015
American Journal of Clinical Nutrition
In new study, Illinois scientists trace activity of cancer-fighting tomato component
Years of research in University of Illinois scientist John Erdman's laboratory have demonstrated that lycopene, the bioactive red pigment found in tomatoes, reduces growth of prostate tumors in a variety of animal models. 'Now our team has learned to grow tomato plants in suspension culture that produce lycopene molecules with a heavier molecular weight. We can trace lycopene's activity in the body,' said John W. Erdman Jr., a U of I professor of nutrition.
National Institutes of Health

Contact: Phyllis Picklesimer
p-pickle@illinois.edu
217-244-2827
University of Illinois College of Agricultural, Consumer and Environmental Sciences

Public Release: 12-Nov-2015
Journal of NeuroOncology
TGen identifies drug that could limit the spread of deadly brain tumors
In a significant breakthrough, the Translational Genomics Research Institute has identified a drug, propentofylline or PPF, that could help treat patients with deadly brain cancer. In a study published today in the Journal of NeuroOncology, TGen researchers report that PPF works to limit the spread of glioblastoma multiforme, or GBM -- the most common primary tumor of the brain and central nervous system -- by targeting a protein called TROY.
Ben & Catherine Ivy Foundation, National Institutes of Health

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute

Public Release: 12-Nov-2015
Biomaterials
Cornell engineers develop 'killer cells' to destroy cancer in lymph nodes
Cornell biomedical engineers have developed specialized white blood cells -- dubbed 'super natural killer cells' -- that seek out cancer cells in lymph nodes with only one purpose: destroy them. This breakthrough halts the onset of metastasis, according to a new Cornell study published this month in the journal Biomaterials.
Lynda's Kause Inc.

Contact: Daryl Lovell
dal296@cornell.edu
607-592-3925
Cornell University

Public Release: 12-Nov-2015
Developmental Cell
Protein's work in eye lens suggests a way to tame cancer
How does a protein called connexin put the clamps on cancer? Researchers in the School of Medicine at the University of Texas Health Science Center at San Antonio today reported an explanation.
NIH/National Eye Institute, National Institutes of Health

Contact: Will Sansom
sansom@uthscsa.edu
210-567-2579
University of Texas Health Science Center at San Antonio

Public Release: 11-Nov-2015
Clinical Cancer Research
First-in-class investigational therapeutic shows early promise for lymphoma patients
Results from a phase I clinical trial showed that the first-in-class, investigational, anticancer therapeutic pevonedistat was safe, tolerable, and had some anticancer activity in heavily pretreated patients with relapsed/refractory lymphoma.
Millennium Pharmaceuticals, Inc.

Contact: Lauren Riley
lauren.riley@aacr.org
215-446-7155
American Association for Cancer Research

Public Release: 11-Nov-2015
Science Translational Medicine
Blood test detects when hormone treatment for breast cancer stops working
Scientists have developed a highly sensitive blood test that can spot when breast cancers become resistant to standard hormone treatment, and have demonstrated that this test could guide further treatment. The test gives an early warning of resistance to aromatase inhibitors, which are used to treat women with oestrogen receptor (ER)-positive breast cancer, the most common kind.
NIHR Biomedical Research Centre at the Royal Marsden, Institute of Cancer Research, Breast Cancer Now, Cridlan Ross Smith Charitable Trust, Cancer Research UK

Contact: Claire Hastings
chastings@icr.ac.uk
020-715-35380
Institute of Cancer Research

Public Release: 11-Nov-2015
The Lancet
Researchers call for investment in cancer control in low- and middle-income countries
Investments in cancer control -- prevention, detection, diagnosis, treatment, and palliative care -- are increasingly needed in low- and, particularly, middle-income countries, where most of the world's cancer deaths occur, a paper published today in The Lancet recommends.
Bill and Melinda Gates Foundation, NIH/National Cancer Institute, Canadian Institutes of Health Research

Contact: Leslie Shepherd
shepherdl@smh.ca
416-864-6094
St. Michael's Hospital

Public Release: 11-Nov-2015
Nature
Change in a single DNA base drives a childhood cancer
Pediatric oncology researchers have pinpointed a crucial change in a single DNA base that both predisposes children to an aggressive form of the childhood cancer neuroblastoma and makes the disease progress once tumors form. The gene change results in a 'super enhancer' that drives the cancer.
National Institutes of Health, PressOn Foundation, Andrew's Army Foundation, Alex's Lemonade Stand Foundation, Brooke Mulford Foundation

Contact: John Ascenzi
Ascenzi@email.chop.edu
267-426-6055
Children's Hospital of Philadelphia

Public Release: 11-Nov-2015
New England Journal of Medicine
Melanoma's genetic trajectories are charted in new study
An international team of scientists led by UCSF researchers has mapped out the genetic trajectories taken by melanoma as it evolves from early skin lesions, known as precursors, to malignant skin cancer.

Contact: Pete Farley
peter.farley@ucsf.edu
415-502-6397
University of California - San Francisco

Public Release: 11-Nov-2015
Journal of Clinical Investigation
Natural selection and inflammation may hold key to age-associated cancer risk
CU Cancer Center studies show how changes in the tissue ecosystem may allow cancer cells to out-compete their healthy rivals.
National Institutes of Health, UNCF/Merck Science Initiative

Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Anschutz Medical Campus

Public Release: 11-Nov-2015
Journal of Palliative Medicine
Researchers call for hospitals to establish bereavement programs
Backed by a growing body of research, investigators at Dana-Farber Cancer Institute are calling for all hospitals to establish bereavement programs for families of deceased patients.

Contact: Anne Doerr
anne_doerr@dfci.harvard.edu
617-632-4090
Dana-Farber Cancer Institute

Public Release: 11-Nov-2015
Blood
World first blood cancer drug trial reveals life-changing results
Clinicians from the University of Leicester and Leicester's Hospitals lead an international clinical trial for patients with blood cancer.
ONO Pharmaceuticals, Scott-Waudby Charitable Trust

Contact: Jenny McNair
jm65@le.ac.uk
01-162-523-170
University of Leicester

Public Release: 11-Nov-2015
Journal of the American Chemical Society
Dendrimer technology gets a grip on cell proteins, could improve cancer treatment
Purdue researchers have devised a way to capture the finer details of complex cell processes by using tiny synthetic particles known as dendrimers, a technology that could lead to more targeted treatment for cancer.
National Institutes of Health, Purdue University Center for Cancer Research

Contact: Natalie van Hoose
nvanhoos@purdue.edu
765-496-2050
Purdue University

Public Release: 11-Nov-2015
Nature
Study reveals why chemotherapy may be compromised in patients with pancreatic cancer
A study at The University of Texas MD Anderson Cancer Center may explain why chemotherapy drugs such as gemcitabine are not effective for many pancreatic cancer patients, and perhaps point to new approaches to treatment including enhancing gemcitabine's ability to stop tumor growth.

Contact: Ron Gilmore
rlgilmore1@mdanderson.org
713-745-1898
University of Texas M. D. Anderson Cancer Center

Public Release: 11-Nov-2015
Previous oral contraceptive use associated with better outcomes in patients with ovarian cancer
Patients who develop ovarian cancer appear to have better outcomes if they have a history of oral contraceptive use, according to a study by Mayo Clinic researchers published in the current issue of the journal BMC Cancer.
National Institutes of Health, NIH/National Cancer Institute

Contact: Joe Dangor
newsbureau@mayo.edu
507-284-5005
Mayo Clinic

Public Release: 10-Nov-2015
Proceedings of the National Academy of Sciences
Rare Her2 mutations may not always spur breast cancers on their own
Results of a new laboratory study by Johns Hopkins Kimmel Cancer Center researchers suggests that some rare 'missense' mutations in the HER2 gene are apparently not -- on their own -- capable of causing breast cancer growth or spread.
Avon Foundation, NIH/National Cancer Institute, Conquer Cancer Foundation, Breast Cancer Specialized Program of Research Excellence, Vanderbilt-Ingram Cancer Center

Contact: Vanessa Wasta
wasta@jhmi.edu
410-614-2916
Johns Hopkins Medicine

Public Release: 10-Nov-2015
ACS Nano
Revolutionary new weapon in air pollution fight
People could soon be using their smartphones to combat a deadly form of air pollution, thanks to a potentially life-saving breakthrough by RMIT University researchers.

Contact: Greg Thom
greg.thom@rmit.edu.au
049-930-1905
RMIT University

Public Release: 10-Nov-2015
Nature Cell Biology
The secret to safe DNA repair
New research from the University of Alberta's Faculty of Medicine & Dentistry is shedding important light on the DNA repair process and a protein newly discovered to have an essential role in preventing errors and mutations from occurring.
Canadian Institutes of Health Research, Alberta Innovates Health Solutions, Alberta Cancer Foundation, Canada Research Chairs program

Contact: Ross Neitz
rneitz@ualberta.ca
780-492-5986
University of Alberta Faculty of Medicine & Dentistry

Showing releases 1201-1225 out of 1310.

<< < 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 > >>

  Search News Releases

     

 

EurekAlert!